Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants

  • Authors:
    • Shiho Asaka
    • Akihiko Yoshizawa
    • Kazusa Saito
    • Yukihiro Kobayashi
    • Hiroshi Yamamoto
    • Tatsuya Negishi
    • Rie Nakata
    • Kazuyuki Matsuda
    • Akemi Yamaguchi
    • Takayuki Honda
  • View Affiliations

  • Published online on: March 27, 2018     https://doi.org/10.3892/ijo.2018.4334
  • Pages: 2110-2118
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidermal growth factor receptor (EGFR) mutations are associated with responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). Our previous study revealed a rapid point-of-care system for detecting EGFR mutations. This system analyzes cell pellets from cytology specimens using droplet-polymerase chain reaction (d-PCR), and has a reaction time of 10 min. The present study aimed to validate the performance of the EGFR d-PCR assay using cell-free DNA (cfDNA) from supernatants obtained from cytology specimens. Assay results from cfDNA supernatant analyses were compared with those from cell pellets for 90 patients who were clinically diagnosed with, or suspected of having, lung cancer (80 bronchial lavage fluid samples, nine pleural effusion samples and one spinal fluid sample). EGFR mutations were identified in 12 and 15 cases using cfDNA supernatants and cell pellets, respectively. The concordance rates between cfDNA-supernatant and cell‑pellet assay results were 96.7% [kappa coefficient (K)=0.87], 98.9% (K=0.94), 98.9% (K=0.79) and 98.9% (K=0.79) for total EGFR mutations, L858R, E746_A750del and T790M, respectively. All 15 patients with EGFR mutation-positive results, as determined by EGFR d-PCR assay using cfDNA supernatants or cell pellets, also displayed positive results by conventional EGFR assays using tumor tissue or cytology specimens. Notably, EGFR mutations were even detected in five cfDNA supernatants for which the cytological diagnoses of the corresponding cell pellets were ‘suspicious for malignancy’, ‘atypical’ or ‘negative for malignancy.’ In conclusion, this rapid point-of-care system may be considered a promising novel screening method that may enable patients with NSCLC to receive EGFR-TKI therapy more rapidly, whilst also reserving cell pellets for additional morphological and molecular analyses.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 52 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Asaka S, Yoshizawa A, Saito K, Kobayashi Y, Yamamoto H, Negishi T, Nakata R, Matsuda K, Yamaguchi A, Honda T, Honda T, et al: Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants. Int J Oncol 52: 2110-2118, 2018.
APA
Asaka, S., Yoshizawa, A., Saito, K., Kobayashi, Y., Yamamoto, H., Negishi, T. ... Honda, T. (2018). Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants. International Journal of Oncology, 52, 2110-2118. https://doi.org/10.3892/ijo.2018.4334
MLA
Asaka, S., Yoshizawa, A., Saito, K., Kobayashi, Y., Yamamoto, H., Negishi, T., Nakata, R., Matsuda, K., Yamaguchi, A., Honda, T."Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants". International Journal of Oncology 52.6 (2018): 2110-2118.
Chicago
Asaka, S., Yoshizawa, A., Saito, K., Kobayashi, Y., Yamamoto, H., Negishi, T., Nakata, R., Matsuda, K., Yamaguchi, A., Honda, T."Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants". International Journal of Oncology 52, no. 6 (2018): 2110-2118. https://doi.org/10.3892/ijo.2018.4334